295 related articles for article (PubMed ID: 38087131)
1. Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.
Zhang G; Deng L; Lu H; Zhang W
Int J Clin Pharm; 2024 Feb; 46(1):186-194. PubMed ID: 38087131
[TBL] [Abstract][Full Text] [Related]
2. Current status and future prospects of chimeric antigen receptor-T cell therapy in lymphoma research: A bibliometric analysis.
Ou L; Su C; Liang L; Duan Q; Li Y; Zang H; He Y; Zeng R; Li Y; Zhou H; Xiao L
Hum Vaccin Immunother; 2023 Dec; 19(3):2267865. PubMed ID: 37846106
[TBL] [Abstract][Full Text] [Related]
3. Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021.
Ou Z; Qiu L; Rong H; Li B; Ren S; Kuang S; Lan T; Lin H; Li Q; Wu F; Cai T; Yan L; Ye Y; Fan S; Li J
Front Immunol; 2022; 13():822004. PubMed ID: 35432345
[TBL] [Abstract][Full Text] [Related]
4. A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022.
Zhang J; Chen P; Miao L
Front Immunol; 2022; 13():969196. PubMed ID: 36032149
[TBL] [Abstract][Full Text] [Related]
5. Global hotspots and future prospects of chimeric antigen receptor T-cell therapy in cancer research: a bibliometric analysis.
Liu M; Gao Y; Yuan Y; Shi S; Yang K; Wu J; Zhang J; Tian J
Future Oncol; 2020 Apr; 16(10):597-612. PubMed ID: 32207326
[No Abstract] [Full Text] [Related]
6. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
7. Global research trends in immunotherapy for glioma: a comprehensive visualization and bibliometric analysis.
Zhang HY; Yu HY; Zhao GX; Jiang XZ; Gao G; Wei BJ
Front Endocrinol (Lausanne); 2023; 14():1273634. PubMed ID: 37867521
[TBL] [Abstract][Full Text] [Related]
8. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
Sun W; Liang AB; Huang H; Huang XJ
Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
[TBL] [Abstract][Full Text] [Related]
9. A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.
Miao L; Zhang J; Zhang Z; Wang S; Tang F; Teng M; Li Y
Front Immunol; 2022; 13():840956. PubMed ID: 35371087
[TBL] [Abstract][Full Text] [Related]
10. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
11. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
12. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.
Huang J; Huang X; Huang J
Front Immunol; 2022; 13():1019115. PubMed ID: 36248810
[TBL] [Abstract][Full Text] [Related]
13. Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012-2023).
Miao L; Zhang J; Xu W; Qian Q; Zhang G; Yuan Q; Lv Y; Zhang H; Shen C; Wang W
Hum Vaccin Immunother; 2024 Dec; 20(1):2338984. PubMed ID: 38698555
[TBL] [Abstract][Full Text] [Related]
14. A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023.
Li H; Huang Q; Zhang Y
Hum Vaccin Immunother; 2023 Dec; 19(3):2291900. PubMed ID: 38112002
[TBL] [Abstract][Full Text] [Related]
15. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.
Sun W; Jiang Z; Jiang W; Yang R
Cancer Treat Res Commun; 2022; 33():100638. PubMed ID: 36184307
[TBL] [Abstract][Full Text] [Related]
16. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
Yang Z; Wang Y
Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
Ho M; Zanwar S; Paludo J
Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
19. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.
Abbasi S; Totmaj MA; Abbasi M; Hajazimian S; Goleij P; Behroozi J; Shademan B; Isazadeh A; Baradaran B
Cancer Med; 2023 Apr; 12(7):7844-7858. PubMed ID: 36583504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
